MAP2K7 and neoplasm: Taken together, our findings provide strong evidence that MEK pathway activation in the tumor drives inhibition of immunogenicity, given that inhibiting MEK increases MHC-I, and thus improves TIL recognition of tumor antigens, leading to enhanced cytotoxic responses.